Ad-hoc | 20 April 2015 17:25


Carl Zeiss Meditec achieves further revenue growth in first half of 2014/15 – Negative result from currency hedging

Carl Zeiss Meditec AG  / Key word(s): Half Year Results

20.04.2015 17:25

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Jena, 20 April 2015: Carl Zeiss Meditec (ISIN: DE0005313704) has achieved
revenue of approximately EUR 498 million in the first half of FY 2014/15,
based on preliminary data. This corresponds to a growth rate vs. the
previous year of approx. 8%. This result was supported by currency effects.
On a constant currency basis, growth vs. the previous year amounted to
approx. 4%.

Earnings before interest & taxes (EBIT) for the first half of FY 2014/15
amounted to approx. EUR 61 million, a decline of 4% vs. the previous year,
resulting in an EBIT margin of 12.2% (PY: 13.8%). Adjusted for additional
strategic research & development expenses in the area of ophthalmology, as
announced in December 2014, EBIT would have reached approx. EUR 68 million,
which is 5% above the comparable previous year's value.

Earnings per share (EPS) are expected at around EUR 0.37. This corresponds
to a decline of 24% vs. the previous year and is mainly related to a
negative result from currency hedging.

EBIT margin is expected to be within a range of 13-15% in the mid-term. In
the current business year, the EBIT margin is also expected to be within
this range, if adjusted for the additional strategic research & development
expenses in the area of ophthalmology.


20.04.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Carl Zeiss Meditec AG
              Göschwitzer Str. 51-52
              07745 Jena
              Germany
Phone:        +49 (0)3641 220-0
Fax:          +49 (0)3641 220-112
E-mail:       investors.meditec@zeiss.com,info.meditec@zeiss.com
Internet:     www.meditec.zeiss.de
ISIN:         DE0005313704
WKN:          531370
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated
              Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
              Munich, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------